drugset / Trial / NCT01432223

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

NCT01432223 ↗

Phase 2 Completed 46 enrolled Osaka Medical College
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable breast cancer.

Timeline

Start
2011-09
Primary completion
2013-11
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Nab-paclitaxel Small molecule 260 mg/m2 —